Investigating the efficacy of continuous positive airway pressure (CPAP) in patients receiving radiotherapy treatment for centrally located lung cancer.

Not Applicable

Recruiting

• Conditions: ung Cancer; Lung Cancer; Cancer - Lung - Small cell; Cancer - Lung - Non small cell; Cancer - Lung - Mesothelioma

• Registration Number: ACTRN12618001326280
• Lead Sponsor: Auckland City Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-08-07
• Last Update Posted: 28 March 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Patients who meet the following criteria will be eligible:
-Aged 16 years or older.
- Diagnosed with centrally located lung tumour, defined as within 2cm in all directions of any mediastinal critical structure, including the bronchial tree, esophagus, heart, brachial plexus, major vessels, spinal cord, phrenic nerve and recurrent laryngeal nerve.
- Prescribed (by an Radiation Oncology) a Radiotherapy Treatment of 60Gy in 8 fractions (SABR) or 48Gy in 12 fractions (hypofractionation).
- Meets the current departmental inclusion criteria for a treatment prescription of 60Gy in 8 fractions (SABR) or 48Gy in 12 fractions (hypofractionation).

Exclusion Criteria

Patients that have significant comorbidities that may result in them not tolerating treatment with CPAP (recent surgery, respiratory conditions, inappropriate age, and disabilities).
Patients who are unable to provide informed consent or who refuse to use CPAP.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Geometrical displacement of the lung tumour to surrounding organs at risk (OARs), measured by the displacement distance (mm).[After Radiotherapy treatment planning, approximately 2-4 weeks after CT imaging.];Tumour motion, as assessed by largest tumour motion displacement (mm) throughout the respiratory cycle in three anatomical planes (transverse, sagittal, coronal).[After Radiotherapy treatment planning, approximately 2-4 weeks after CT imaging.];Quality of Radiotherapy treatment plan, assessed by current clinical departmental dosimetric parameters to the tumour and surrounding organs at risk eg. mean dose, V5, V90, D99, D90.[After Radiotherapy treatment planning, approximately 2-4 weeks after CT imaging.]

Secondary Outcome Measures

Name	Time	Method
Patient tolerability of using CPAP during CT imaging, assessed by a study-specific questionnaire given to all study participants that asks about discomfort, symptoms, and patient experience. <br>[Immediately after CT imaging.];Patient tolerability of using CPAP during Radiotherapy treatment, assessed in participants that use CPAP during Radiotherapy treatment by a study-specific questionnaire that assesses discomfort, symptoms, and patient experience. [First, middle, and last Radiotherapy treatment delivery; approximately 6 weeks, 6.5-7weeks, and 7-8 weeks after CT imaging respectively. ]